# Microarray Analysis Market Size, Share, and Trends - Global Forecast 2026-2036 | Population Genotyping, Clinical Cytogenetics, and Asia-Pacific Growth Create a USD 2.58 Billion Opportunity

- Published: 2026-11-16
- Author: [BiotechNews.io](https://biotechnews.io/author/biotechnews-io.md)
- Topics: [News](https://biotechnews.io/news.md)
- Source: https://biotechnews.io/news/microarray-analysis-market-size-share-and-trends-global-forecast-2026-2036-population-geno/
- Publication: Biotech News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://biotechnews.io/editorial-policy/

*Maximize ROI with low-cost array genotyping plus imputation, diverse-ancestry content, agrigenomics expansion, and first-tier testing before sequencing.*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6290665/microarray-analysis-market-size-share-trends?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=43hb5c&amp;utm_campaign=2404372+-+Microarray+Analysis+Market+Size%2c+Share%2c+and+Trends+-+Global+Forecast+2026-2036+%7c+Population+Genotyping%2c+Clinical+Cytogenetics%2c+and+Asia-Pacific+Growth+Create+a+USD+2.58+Billion+Opportunity&amp;utm_exec=clshmsai" rel="nofollow">"Microarray Analysis Market Size, Share, and Trends - Forecast to 2036"</a> has been added to **ResearchAndMarkets.com's** offering.

The global microarray analysis market was valued at USD 1.88 billion in 2025 and is estimated to reach USD 1.92 billion in 2026. It is projected to grow to USD 2.58 billion by 2036, representing a CAGR of 3.0% during the forecast period 2026-2036. The report examines array formats and content, imputation, microarrays versus sequencing, technology substitution, installed base, regulation, reimbursement, cost per sample, supplier positioning, and emerging growth opportunities.

The market includes consumables, instruments, software, and services supporting DNA microarrays, protein and antibody arrays, tissue and cell arrays, and other specialized formats. Recurring expenditure is concentrated in arrays, chips, reagents, and kits, while additional revenue comes from scanners, imaging systems, automation platforms, analysis software, and genotyping and profiling services.

**Market Dynamics and Growth Opportunities**

Microarray analysis remains a mature market as next-generation sequencing continues to replace arrays in gene expression profiling and discovery research. However, arrays retain a strong economic and clinical position in population-scale genotyping, agrigenomics, chromosomal microarray analysis, pharmacogenomics, and polygenic risk assessment. Illumina reported second-quarter 2026 microarrays and other revenue of USD 105 million, compared with USD 775 million from sequencing consumables. Population genomics remains an important source of demand, illustrated by the U.K.'s Our Future Health program, which has processed arrays for 755,000 of more than 2.02 million recruits.

Cost per sample is a central market driver. Large biobanks can measure hundreds of thousands of known variants and use imputation to expand genomic coverage at a substantially lower cost than sequencing. Livestock and crop breeding organizations also depend on economical testing for breeding values, parentage, and trait selection. In clinical settings, reimbursement supports chromosomal microarray analysis for several prenatal and pediatric indications, reinforcing its established role in cytogenetics.

The primary restraint is continued substitution by sequencing, which can identify novel and rare variants beyond predefined array content. Low-pass whole-genome sequencing with imputation presents the most significant long-term competitive challenge, particularly if it reaches cost parity with array-based population genotyping. Periodic payer policy reviews and supplier consolidation also create uncertainty.

Growth opportunities are emerging through ancestry-inclusive array content, pharmacogenomic panels, and national genomics programs in cost-sensitive markets. Thermo Fisher Scientific has expanded its portfolio with biobank-oriented Axiom arrays and the PangenomiX array for diverse populations. Additional opportunities exist in aquaculture, companion animals, small ruminants, crops, and livestock markets across Asia, Latin America, and Africa. Arrays may also serve as a low-cost first-tier test, with sequencing reserved for unresolved cases.

**Segment Outlook**

Consumables are expected to account for the largest product share in 2026 because every processed sample requires an array and associated reagents. Software & services are forecast to record the highest CAGR from a smaller base as cohort programs and breeding organizations increasingly outsource genotyping, imputation, analysis, and interpretation. Instrument growth is expected to remain limited due to the established installed base.

DNA microarrays are projected to lead the market by type and record the highest CAGR, supported by cohort genotyping, agrigenomics, pharmacogenomics, and copy number testing. Protein & antibody microarrays should achieve modest growth in biomarker screening, autoantibody profiling, and immune response research. Tissue & cell microarrays will retain roles in pathology research and antibody validation, although spatial profiling technologies will limit expansion.

Genotyping is expected to remain the largest and fastest-growing application segment in 2026. Its outlook is supported by national cohort initiatives, biobank expansion, pharmacogenomic testing, and polygenic risk applications. Cytogenetics & copy number analysis should maintain a stable share because of established clinical coverage, while agrigenomics is forecast to expand steadily. Gene expression profiling is expected to decline as RNA sequencing adoption increases.

Clinical & diagnostic laboratories are anticipated to represent the largest end-user segment, driven by prenatal, pediatric, and cancer genetics testing. Biobanks & population genomics programs are projected to post the highest CAGR as established programs expand and new initiatives launch in Asia-Pacific and the Middle East.

**Regional Market Trends**

North America is expected to hold the largest share of the microarray analysis market in 2026. Growth is supported by established reimbursement policies, substantial clinical cytogenetics volumes, agricultural genotyping, advanced research infrastructure, and the presence of Illumina, Thermo Fisher Scientific, and Agilent Technologies.

Europe maintains a significant position through large biobank programs, established cytogenetics services, and genomic selection in animal breeding. Asia-Pacific is forecast to achieve the highest CAGR during 2026-2036, supported by national genomics initiatives in China, Japan, India, and Southeast Asia, rising clinical capacity, agricultural modernization, and array content designed for non-European ancestries. Latin American demand is led by cattle and poultry genotyping in Brazil and Argentina, while Gulf countries are investing in national genome programs and clinical genetics infrastructure.

**Competitive Landscape**

The microarray analysis market is concentrated, with Illumina and Thermo Fisher Scientific supplying much of the genotyping and expression array capacity. Agilent Technologies maintains a position in cytogenetics, while RayBiotech and Sengenics specialize in protein and tissue arrays. Eurofins Scientific provides genotyping services, and agricultural genomics remains an active area of strategic investment. In March 2026, Neogen announced the sale of its GeneSeek genomics business, including the Igenity and GGP livestock genotyping portfolios, to Zoetis for USD 160 million.

Competitive differentiation increasingly centers on cost per sample, ancestry coverage, array content, data quality, and imputation support rather than new instrument platforms. Product development is focused on multi-ancestry cohorts, drug-response panels, polygenic applications, and additional agricultural species.

Companies profiled include Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Revvity, Inc., Bio-Rad Laboratories, Inc., Zoetis Inc. (GeneSeek), Eurofins Scientific SE, RayBiotech Life, Inc., Sengenics Corporation LLC, and Merck KGaA.

**Report Benefits**

-   Provides global microarray analysis market size estimates and forecasts through 2036.
-   Evaluates demand across genotyping, cytogenetics, agrigenomics, pharmacogenomics, and biomarker profiling.
-   Assesses sequencing displacement, low-pass whole-genome sequencing, reimbursement changes, and supplier consolidation.
-   Identifies growth opportunities by product, type, application, end user, and region.
-   Compares leading suppliers by portfolio, array content, services, and strategic activity.
-   Supports product planning, market entry, investment, partnership, and portfolio development decisions.

**Key Topics Covered:**  
  
**1\. Introduction**  
1.1. Market Definition  
1.2. Market Ecosystem  
1.3. Currency and Limitations  
1.3.1. Currency  
1.3.2. Limitations  
1.4. Key Stakeholders  
  
**2\. Research Methodology**  
2.1. Research Approach  
2.2. Data Collection & Validation Process  
2.2.1. Secondary Research  
2.2.2. Primary Research & Validation  
2.2.2.1. Primary Interviews with Industry Experts  
2.2.2.2. Country-/Region-Level Analysis  
2.3. Market Estimation  
2.3.1. Bottom-Up Approach  
2.3.2. Top-Down Approach  
2.3.3. Forecast Methodology  
2.4. Data Triangulation  
2.5. Assumptions  
  
**3\. Executive Summary**  
  
**4\. Market Insights**  
4.1. Introduction  
4.2. Market Dynamics  
4.2.1. Drivers  
4.2.1.1. Cost Advantage in Population-Scale Genotyping  
4.2.1.2. Agricultural and Livestock Genomic Selection  
4.2.1.3. Reimbursed Clinical Position in Cytogenetics  
4.2.1.4. Pharmacogenomic and Polygenic Risk Genotyping  
4.2.2. Restraints  
4.2.2.1. Continuing Displacement by Next-Generation Sequencing  
4.2.2.2. Inability to Detect Variation Not Represented on the Array  
4.2.3. Opportunities  
4.2.3.1. Diverse-Ancestry and Pharmacogenomic Array Content  
4.2.3.2. Array-Based Genotyping in National Cohort Programmes Outside Established Markets  
4.2.3.3. Expansion of Agrigenomics into New Species and Markets  
4.2.3.4. Arrays as a First-Tier Test in Tiered Diagnostic Pathways  
4.2.4. Challenges  
4.2.4.1. Encroachment of Low-Pass Whole-Genome Sequencing into Genotyping  
4.2.4.2. Dependence on Clinical Coverage Policy and Supplier Consolidation  
4.2.5. Trends  
4.2.5.1. Concentration of Array Value in Genotyping Rather Than Expression  
4.2.5.2. Complementary Rather Than Competitive Positioning Against Sequencing  
4.2.5.3. Content Development for Diverse Populations and Polygenic Applications  
4.3. Technology Landscape  
4.3.1. Bead-Based and In Situ Synthesised Array Formats  
4.3.2. Array Content Design and Ancestry Coverage  
4.3.3. Imputation and Reference Panels  
4.3.4. Cytogenetic Array Resolution and Interpretation  
4.3.5. Protein and Tissue Array Formats  
4.3.6. Automation and High-Throughput Array Processing  
4.4. Microarrays vs. Next-Generation Sequencing: Comparative Cost and Capability Analysis  
4.5. Technology Substitution Analysis by Application  
4.6. Installed Base and Consumable Pull-Through Analysis  
4.7. Value Chain Analysis  
4.7.1. Array Design and Content Selection  
4.7.2. Array Manufacturing  
4.7.3. Sample Processing and Hybridisation  
4.7.4. Genotype Calling, Imputation, and Analysis  
4.7.5. Interpretation and End Use  
4.8. Regulatory and Reimbursement Landscape  
4.8.1. Clinical Use of Chromosomal Microarray Analysis  
4.8.2. Payer Coverage Policies for CMA and Sequencing  
4.8.3. EU In Vitro Diagnostic Regulation Considerations  
4.8.4. Agricultural Genotyping Standards  
4.9. Porter's Five Forces Analysis  
4.10. Pricing Analysis (Cost per Sample)  
  
**5\. Microarray Analysis Market Assessment, by Product**  
5.1. Introduction  
5.2. Consumables  
5.2.1. Arrays & Chips  
5.2.2. Reagents & Kits  
5.3. Instruments  
5.3.1. Scanners & Imaging Systems  
5.3.2. Hybridisation, Washing & Automation Systems  
5.4. Software & Services  
  
**6\. Microarray Analysis Market Assessment, by Type**  
6.1. Introduction  
6.2. DNA Microarrays  
6.2.1. Genotyping Arrays  
6.2.2. Copy Number & Cytogenetic Arrays  
6.2.3. Methylation Arrays  
6.2.4. Expression Arrays  
6.3. Protein & Antibody Microarrays  
6.4. Tissue & Cell Microarrays  
6.5. Other Microarrays  
  
**7\. Microarray Analysis Market Assessment, by Application**  
7.1. Introduction  
7.2. Genotyping  
7.2.1. Population & Biobank Genotyping  
7.2.2. Pharmacogenomic Genotyping  
7.2.3. Polygenic Risk & Research Genotyping  
7.3. Cytogenetics & Copy Number Analysis  
7.4. Gene Expression Profiling  
7.5. Agrigenomics & Animal Breeding  
7.6. Proteomic & Biomarker Profiling  
7.7. Other Applications  
  
**8\. Microarray Analysis Market Assessment, by End User**  
8.1. Introduction  
8.2. Academic & Research Institutes  
8.3. Biobanks & Population Genomics Programmes  
8.4. Clinical & Diagnostic Laboratories  
8.5. Agricultural & Animal Breeding Organizations  
8.6. Pharmaceutical & Biotechnology Companies  
  
**9\. Microarray Analysis Market Assessment, by Geography**  
9.1. Introduction  
9.2. North America  
9.2.1. U.S.  
9.2.2. Canada  
9.3. Europe  
9.3.1. U.K.  
9.3.2. Germany  
9.3.3. France  
9.3.4. Netherlands  
9.3.5. Nordic Countries  
9.3.6. Rest of Europe  
9.4. Asia-Pacific  
9.4.1. China  
9.4.2. Japan  
9.4.3. India  
9.4.4. South Korea  
9.4.5. Australia  
9.4.6. Rest of Asia-Pacific  
9.5. Latin America  
9.5.1. Brazil  
9.5.2. Argentina  
9.5.3. Mexico  
9.5.4. Rest of Latin America  
9.6. Middle East & Africa  
9.6.1. Saudi Arabia  
9.6.2. UAE  
9.6.3. South Africa  
9.6.4. Rest of Middle East & Africa  
  
**10\. Competition Analysis**  
10.1. Overview  
10.2. Key Growth Strategies  
10.3. Competitive Benchmarking  
10.4. Competitive Dashboard  
10.4.1. Market Leaders  
10.4.2. Market Differentiators  
10.4.3. Vanguards  
10.4.4. Emerging Players  
10.5. Market Share/Rank Analysis, by Key Player, 2025  
  
**11\. Company Profiles**  
(Business Overview, Financial Overview, Microarray Portfolio, Product Portfolio, Strategic Developments, SWOT Analysis)  
11.1. Illumina, Inc.  
11.2. Thermo Fisher Scientific Inc.  
11.3. Agilent Technologies, Inc.  
11.4. Revvity, Inc.  
11.5. Bio-Rad Laboratories, Inc.  
11.6. Zoetis Inc. (GeneSeek)  
11.7. Eurofins Scientific SE  
11.8. RayBiotech Life, Inc.  
11.9. Sengenics Corporation LLC  
11.10. Merck KGaA  
  
**12\. Appendix**  
12.1. Related Reports  
12.2. Customization Options  
  
**List of Tables \[298\]**  
  
**List of Figures \[41\]**  
  
For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6290665/microarray-analysis-market-size-share-trends?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=43hb5c&amp;utm_campaign=2404372+-+Microarray+Analysis+Market+Size%2c+Share%2c+and+Trends+-+Global+Forecast+2026-2036+%7c+Population+Genotyping%2c+Clinical+Cytogenetics%2c+and+Asia-Pacific+Growth+Create+a+USD+2.58+Billion+Opportunity&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/o7pwto</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/ODRjMDBmN2ItM2QyYi00OGFmLTk5ZjEtMzIwNmNjZGI1MmI1LTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [Humanized Mouse and Rat Model - Global Strategic Business Report 2026: Capitalize on 9.7% CAGR to $231.6M by 2032 as Charles River, Biocytogen, Taconic and The Jackson Laboratory reshape drug R&D](https://biotechnews.io/news/humanized-mouse-and-rat-model-global-strategic-business-report-2026-capitalize-on-9-7-cagr.md)
- [In Vivo Contract Research Organization (CRO) Market - Global Forecast 2026-2032 | AI, Advanced Models, and Drug Development Outsourcing Drive 8.42% CAGR Toward USD 9.45 Billion](https://biotechnews.io/news/in-vivo-contract-research-organization-cro-market-global-forecast-2026-2032-ai-advanced-mo.md)
- [Global Full-Spectrum Fluorescence in Vivo Imaging System Market - Forecast 2026-2032 | AI-Enabled Analysis and Preclinical Research Demand Drive 8.02% CAGR Toward USD 4.14 Billion](https://biotechnews.io/news/global-full-spectrum-fluorescence-in-vivo-imaging-system-market-forecast-2026-2032-ai-enab.md)
- [Global Nuclear Receptor Screening Services Market Size, Share, and Trends - Forecast 2026-2032 | AI and Automation Fuel 11.74% CAGR, Creating a USD 2.22 Billion Opportunity](https://biotechnews.io/news/global-nuclear-receptor-screening-services-market-size-share-and-trends-forecast-2026-2032.md)
